ZYBERNO
Stock Report
Updated Aug 21, 2026

MEDIWOUND LTD. (MDWD)

Healthcare • NASDAQ

$13.24

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
MEDIWOUND LTD. (MDWD) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-48.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MEDIWOUND LTD. (MDWD) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.24
Market Cap:$169.94M

Valuation Multiples (3)

P/B Ratio:3.89x
P/S Ratio:10.02x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$165.14M

Price Action & Momentum (3)

Momentum Percentile:20 / 100
% of 52-Week High:65.2%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-19.2%
Fundamental Growth Rate (g):9.4%

Margin Analysis (1)

Ebitda Margin:-138.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):30.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.33x
Quick Ratio:2.17x
Cash Ratio:0.19x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-2.53x
Times Interest Earned:-2.53

Capital Structure (4)

Working Capital:34,256,000.00
Cash And Cash Equivalents:4,799,000.00
Long Term Debt:$0.00
Net Debt:-$4.80M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $16.96M
Linear Growth: 30.3%
📊 Click to view full MDWD Revenue analysis & methodology →
Cost Of Revenue Ttm:$13.71M

Profitability Breakdown (2)

Gross profit TTM: $3.25M
Linear Growth: 13.5%
📊 Click to view full MDWD Gross Profit analysis & methodology →
-$25.27M

Bottom Line Performance (3)

-$23.88M
Income Before Tax:$0.00
Ebitda Ttm:-23,406,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:$73.00K
Interest Expense:9,972,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:-138.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$86.26M
Current Assets:$59.96M
Ppe Net:18,640,000.00
Goodwill:0.00
Intangible Assets:$33.00K

Liability Structure (4)

Total Liabilities:42,623,000.00
Current Liabilities:25,708,000.00
Long Term Debt:$0.00
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$43.63M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:4,093,000.00
Accounts Payable:3,607,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.12M-$21.63M

Investment Activities (1)

Investing Cash Flow:$7.54M

Financing Activities (3)

Financing Cash Flow:$549.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.86

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.32
Operating Cash Flow Per Share:-$1.26

Book Value & Capital (2)

Book Value Per Share:$3.40
Cash Per Share:0.37

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.20x
Working Capital Turnover Ttm:0.50x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:3.35x
Days Inventory Outstanding Ttm:109.01

Payables & Cash Cycle (2)

Days Payable Outstanding:96.06
Cash Conversion Cycle:-986.06
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-19.2%
Fundamental Growth Rate (g):9.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):30.3%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):13.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:MDWD
Company Name:MEDIWOUND LTD.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Israel

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:12.84M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-21 17:38:56 UTC
Data Timestamp:2026-08-19T00:13:59.247025
Scroll to Top